Cerenome, Inc.
Cerenome, Inc.
- Market cap
- $6.16M
Your view on CNSY
Overview
What the company does, where it operates, and who runs it.
About Cerenome, Inc.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Marc H. Hedrick
- Headquarters
- Houston, TX, US
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Marc H. Hedrick
- Headquarters
- Houston, TX, US
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J.
Calhoun in July 1996 and is headquartered in Houston, TX.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Cerenome, Inc.. Starting points for Cerenome, Inc.: EPS -$4.01, beta 1.49 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Cerenome, Inc.. Trailing twelve-month EPS for Cerenome, Inc. stands at -$4.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Cerenome, Inc.. Cerenome, Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| AIBTAibotics Inc. | Healthcare | OTC | $484,674 | ||
| AJOYAyujoy Herbals Ltd. | Healthcare | OTC | $103,731 | ||
| AJYGAJ1G, Inc. | Healthcare | OTC | $928,056 | ||
| ALSTAllstar Health Brands, Inc. | Healthcare | OTC | $6,759 | ||
| AOXGAoxing Pharmaceutical Company, Inc. | Healthcare | OTC | $381,080 | ||
| AREVFAREV Life Sciences Global Corp. | Healthcare | OTC | $15,881 | ||
| ATTBFAbattis Bioceuticals Corp. | Healthcare | OTC | — | ||
| BDPTBioAdaptives, Inc. | Healthcare | OTC | $197,978 | ||
| BFRIBiofrontera Inc. | Healthcare | NASDAQ | $7.9M | ||
| BFRIWBiofrontera Inc. | Healthcare | NASDAQ | $796,653 | ||
| BGMSBio Green Med Solution, Inc. | Healthcare | NASDAQ | $3.1M | ||
| BGXXQBright Green Corporation | Healthcare | PNK | — | ||
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Cerenome, Inc., and how their positions are changing. At a $6.2M market value, institutional positions materially move Cerenome, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Cerenome, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Cerenome, Inc.. Coverage tracks Cerenome, Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Cerenome, Inc.